NovoCure Ltd (NASDAQ:NVCR)’s traded shares stood at 0.5 million during the last session, with the company’s beta value hitting 0.71. At the close of trading, the stock’s price was $14.72, to imply an increase of 1.24% or $0.18 in intraday trading. The NVCR share’s 52-week high remains $24.74, putting it -68.07% down since that peak but still an impressive 26.15% since price per share fell to its 52-week low of $10.87. The company has a valuation of $1.59B, with an average of 0.75 million shares in intraday trading volume over the past 10 days and average of 1.05 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for NovoCure Ltd (NVCR), translating to a mean rating of 2.14. Of 5 analyst(s) looking at the stock, 1 analyst(s) give NVCR a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 1 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
After registering a 1.24% upside in the last session, NovoCure Ltd (NVCR) has traded red over the past five days. The 5-day price performance for the stock is -5.70%, and -18.45% over 30 days. With these gigs, the year-to-date price performance is -1.41%. Short interest in NovoCure Ltd (NASDAQ:NVCR) saw shorts transact 6.11 million shares and set a 5.61 days time to cover.
The extremes give us $14.5 and $200 for target low and target high price respectively. As such, NVCR has been trading -1258.7% off suggested target high and 1.49% from its likely low.
NovoCure Ltd (NVCR) estimates and forecasts
Looking at statistics comparing NovoCure Ltd share performance against respective industry, we note that the company has outperformed competitors. NovoCure Ltd (NVCR) shares are 7.13% up over the last 6 months, with its year-to-date growth rate higher than industry average at 31.28% against 17.60%.
NVCR Dividends
NovoCure Ltd has its next earnings report out on 2024-Oct-30. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
NovoCure Ltd insiders hold 9.23% of total outstanding shares, with institutional holders owning 86.56% of the shares at 95.36% float percentage. In total, 86.56% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 16.14 million shares (or 15.0482% of shares), all amounting to roughly $276.51 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 12.13 million shares, or about 11.3106% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $207.83 million.
